In a significant leadership transition, Dame Emma Walmsley has announced her decision to step down as CEO of GSK after eight years at the helm. The change, effective from January 1, 2026, will see current Chief Commercial Officer Luke Miels assume the top role, while Walmsley remains with the company in an advisory capacity until September of that year.
Walmsley, the first woman to lead a major pharmaceutical company, described 2026 as a “pivotal year” for GSK. “It’s the right time for a leadership transition,” she stated, highlighting her pride in strengthening the company’s focus on innovation and biopharma. Under her leadership, GSK spun off its consumer healthcare arm into Haleon—a £29 billion standalone business—and made strategic investments in vaccine development and drug innovation. She earned over £10 million in total pay last year.
Her exit comes at a time of broader turbulence within the pharmaceutical sector. Industry giants like Merck and Eli Lilly have publicly criticized the UK’s regulatory and pricing environment, with some pausing or abandoning major investments. AstraZeneca, another FTSE 100 pharma leader, recently announced plans to list in New York while maintaining its UK headquarters—another sign of shifting industry dynamics.
Despite these challenges, GSK has seen pockets of success. The company anticipates five major regulatory approvals in 2025 and has resolved its involvement in the costly Zantac litigation. Still, analysts note that share performance has remained flat, and GSK continues to trade at a discount compared to global peers.
Derren Nathan, head of equity research at Hargreaves Lansdown, commented that while Walmsley delivered consistent financial results, growth has been modest. “It will be up to Luke Miels to unlock further potential,” he said. “The market has responded positively so far, but the real test lies ahead.”
Walmsley expressed confidence in Miels, calling him the right leader to carry the momentum forward. “GSK’s strength lies in its people and its purpose,” she said. “I look forward to supporting the transition and cheering on the company’s future successes.”
GSK, currently valued at £60 billion and one of the largest firms in the FTSE 100, employs over 65,000 people worldwide and delivers more than 1 million vaccine doses daily. As it prepares for a new chapter, all eyes will be on Miels to guide the company through an increasingly complex global landscape.
